Compare Stocks: MOLN, PRME, MDXG, and SVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDXG MiMedx Group	$4.43 -2.6%	$4.23	$3.03 ▼ $7.97	$645.72M	1.43	1.29 million shs	429,669 shs
MOLN Molecular Partners	$4.30 +5.6%	$4.10	$3.53 ▼ $5.36	$173.53M	1.09	4,719 shs	277 shs
PRME Prime Medicine	$3.63 -1.1%	$3.38	$2.67 ▼ $6.94	$658.40M	2.34	2.89 million shs	1.47 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDXG MiMedx Group	+0.66%	+2.94%	+6.56%	+20.37%	-36.72%
MOLN Molecular Partners	-0.61%	-5.53%	+0.57%	+7.66%	+10.34%
PRME Prime Medicine	+2.80%	+2.51%	+30.60%	+5.76%	+17.63%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDXG MiMedx Group	$4.43 -2.6%	$4.23	$3.03 ▼ $7.97	$645.72M	1.43	1.29 million shs	429,669 shs
MOLN Molecular Partners	$4.30 +5.6%	$4.10	$3.53 ▼ $5.36	$173.53M	1.09	4,719 shs	277 shs
PRME Prime Medicine	$3.63 -1.1%	$3.38	$2.67 ▼ $6.94	$658.40M	2.34	2.89 million shs	1.47 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.8	N/A	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDXG MiMedx Group	+0.66%	+2.94%	+6.56%	+20.37%	-36.72%
MOLN Molecular Partners	-0.61%	-5.53%	+0.57%	+7.66%	+10.34%
PRME Prime Medicine	+2.80%	+2.51%	+30.60%	+5.76%	+17.63%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	93.49% Upside
MOLN Molecular Partners	2.25	Hold	$8.38	94.86% Upside
PRME Prime Medicine	2.89	Moderate Buy	$7.47	105.85% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MOLN, PRME, MDXG, and SVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/18/2026	PRME Prime Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
8/18/2026	PRME Prime Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
8/13/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/10/2026	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDXG MiMedx Group	$418.63M	1.54	$0.54 per share	8.16	$1.48 per share	2.99
MOLN Molecular Partners	N/A	N/A	N/A	N/A	$1.83 per share	N/A
PRME Prime Medicine	$4.07M	161.65	N/A	N/A	$0.22 per share	16.50
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$64.88 per share	0.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDXG MiMedx Group	$48.58M	$0.04	110.78	26.06	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
MOLN Molecular Partners	-$74.41M	-$1.71	N/A	N/A	N/A	N/A	-68.36%	-54.82%	10/29/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MOLN, PRME, MDXG, and SVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	MOLN Molecular Partners	-$0.45	-$0.44	+$0.01	-$0.43	N/A	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	39.83%	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDXG MiMedx Group	0.07	5.33	4.79
MOLN Molecular Partners	N/A	7.27	7.27
PRME Prime Medicine	N/A	3.05	3.05
SVA Sinovac Biotech	0.04	6.07	5.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDXG MiMedx Group	79.15%
MOLN Molecular Partners	26.55%
PRME Prime Medicine	70.37%
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
MDXG MiMedx Group	2.50%
MOLN Molecular Partners	5.93%
PRME Prime Medicine	16.04%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
PRME Prime Medicine	N/A	181.38 million	152.28 million	N/A
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable

MOLN, PRME, MDXG, and SVA Headlines

Recent News About These Companies

Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA

July 21, 2026 | benzinga.com

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

July 15, 2026 | businesswire.com

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

July 12, 2026 | businesswire.com

Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report

June 15, 2026 | tipranks.com

Sinovac Biotech Ltd.

June 8, 2026 | edition.cnn.com

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

June 5, 2026 | businesswire.com

Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance

May 29, 2026 | tipranks.com

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

May 29, 2026 | businesswire.com

SVA Share News Today

May 16, 2026 | uk.investing.com

SINOVAC Reports Unaudited First Half of 2025 Financial Results

May 8, 2026 | businesswire.com

Sinovac Biotech Delays Key Annual 20-F Filing

April 30, 2026 | tipranks.com

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

April 30, 2026 | businesswire.com

Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.

March 28, 2026 | tennessean.comT

Sinovac Controlling Shareholders Escape Investor Disclosure Suit

February 25, 2026 | news.bloomberglaw.comN

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

January 22, 2026 | businesswire.com

Sinovac Biotech receives Nasdaq notification regarding late filing of FY25

January 4, 2026 | msn.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | financialpost.comF

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

January 4, 2026 | businesswire.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | businesswire.com

Antigua High Court gives Sinovac Biotech board control until trial

December 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, PRME, MDXG, and SVA Company Descriptions

MiMedx Group NASDAQ:MDXG

$4.43 -0.12 (-2.64%)

As of 02:45 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Molecular Partners NASDAQ:MOLN

$4.30 +0.23 (+5.60%)

As of 02:14 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Prime Medicine NASDAQ:PRME

$3.63 -0.04 (-1.09%)

As of 02:45 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 09/2/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, PRME, MDXG, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, PRME, MDXG, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, PRME, MDXG, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, PRME, MDXG, and SVA Company Descriptions

MiMedx Group NASDAQ:MDXG

Molecular Partners NASDAQ:MOLN

Prime Medicine NASDAQ:PRME

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MOLN, PRME, MDXG, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MOLN, PRME, MDXG, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MOLN, PRME, MDXG, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, PRME, MDXG, and SVA Company Descriptions

MiMedx Group NASDAQ:MDXG

Molecular Partners NASDAQ:MOLN

Prime Medicine NASDAQ:PRME

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools